What is HC Wainwright’s Estimate for FHTX Q3 Earnings?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – HC Wainwright raised their Q3 2026 earnings estimates for shares of Foghorn Therapeutics in a report issued on Friday, May 8th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.28) per share for the quarter, up from their prior estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.03) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($1.06) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.04) EPS and FY2030 earnings at $0.36 EPS.

Other equities research analysts also recently issued reports about the stock. Wedbush reissued an “outperform” rating and issued a $10.00 price objective on shares of Foghorn Therapeutics in a research report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Foghorn Therapeutics in a research report on Tuesday, April 21st. Jefferies Financial Group reissued a “buy” rating on shares of Foghorn Therapeutics in a research report on Thursday, March 12th. Finally, Wall Street Zen downgraded shares of Foghorn Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.13.

Foghorn Therapeutics Trading Down 2.5%

Shares of NASDAQ:FHTX opened at $4.33 on Tuesday. Foghorn Therapeutics has a 52 week low of $3.27 and a 52 week high of $6.95. The company’s 50 day moving average is $5.02 and its two-hundred day moving average is $5.06. The company has a market cap of $254.21 million, a PE ratio of -3.73 and a beta of 2.97.

Foghorn Therapeutics (NASDAQ:FHTX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). The business had revenue of $3.27 million for the quarter, compared to the consensus estimate of $7.94 million.

Institutional Trading of Foghorn Therapeutics

A number of large investors have recently bought and sold shares of FHTX. AQR Capital Management LLC acquired a new stake in Foghorn Therapeutics during the 1st quarter worth $68,000. Geode Capital Management LLC boosted its stake in Foghorn Therapeutics by 16.9% during the 2nd quarter. Geode Capital Management LLC now owns 807,674 shares of the company’s stock worth $3,797,000 after purchasing an additional 116,979 shares during the period. JPMorgan Chase & Co. boosted its stake in Foghorn Therapeutics by 16.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 18,723 shares of the company’s stock worth $88,000 after purchasing an additional 2,597 shares during the period. Rhumbline Advisers boosted its stake in Foghorn Therapeutics by 21.9% during the 2nd quarter. Rhumbline Advisers now owns 44,165 shares of the company’s stock worth $208,000 after purchasing an additional 7,920 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Foghorn Therapeutics by 18.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,908 shares of the company’s stock worth $84,000 after purchasing an additional 2,812 shares during the period. Institutional investors and hedge funds own 61.55% of the company’s stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.